CYTOKINETICS

📅 Upcoming

🕒 Recent(90d)

News

• Braveheart pumps more life into biotech IPO market with $382M expected debut
  Braveheart Bio has emerged on the Nasdaq with an upsized expected initial public offering—marking the public entrance of the twenty-second biotech this year.
  biospace · 5d ago
• Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
  Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
  fiercebiotech · 6d ago
• Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
  Attovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.
  fiercebiotech · 12d ago
• Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
  Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
  raps · 13d ago
• Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
  Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is lookin…
  biospace · 26d ago
• Braveheart, Attovia join next wave of biotech IPOs
  The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
  biopharma_dive · 27d ago
• Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival
  Biotechs are sprinting to the IPO queue. In the industry's fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel Phase 3 testing of a cardio drug that could potentially…
  endpoints · 27d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Edgewise heart drug passes key trial test
  Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.
  biopharma_dive · 1mo ago
• Create Medicines raises $122M to bolster in vivo CAR-T therapies
  The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
  biopharma_dive · 2mo ago